ASTH vs VCEL: Which Stock Is the Better Buy?
Astrana Health, Inc. and Vericel Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ASTH vs VCEL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Astrana Health, Inc. (ASTH) | Vericel Corporation (VCEL) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $3.18B | $276.26M |
| Net income (latest FY) | $22.49M | $16.52M |
| Revenue growth (5y CAGR) | 35.9% | 17.3% |
| Net margin | 0.7% | 6.0% |
| Return on equity | 2.9% | 4.7% |
| P/E ratio | 62.6 | 86.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 3 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ASTH vs VCEL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ASTH's full financials → Open VCEL's full financials →More comparisons
Frequently asked questions
Which is bigger, ASTH or VCEL?
Vericel Corporation is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, ASTH or VCEL?
Over the last five fiscal years, Astrana Health, Inc. grew revenue faster — 35.9%/yr versus 17.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ASTH fundamentals → · VCEL fundamentals → · All 1,500+ companies → · Free screener →